Delivery Order SPE2DB22D9309-SPE2DB25FAF12
- Not listed
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, has been awarded a firm fixed-price delivery order valued at $1,712.23 by the Defense Logistics Agency (DLA) for the supply of Xolair 300 mg/2 ml auto-injector vials. The delivery order, issued on September 3, 2025, with an ultimate completion date of September 24, 2025, carries no set-aside designation. This award is issued under DMS Pharmaceutical Group's existing single-award...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $6,848.88 by the Defense Logistics Agency (DLA) on September 3, 2025. The contract calls for the delivery of Xolair 150 mg/ml auto-injector medication, with an ultimate completion date of September 24, 2025. No set-aside designation was applied to this award. This delivery order is issued under DMS Pharmaceutical Group's...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $3,424.44 by the Defense Logistics Agency (DLA) on August 7, 2025, for the supply of XOLAIR 150 mg/ml autoinjector medication. The contract carries a firm fixed-price structure with an ultimate completion date of August 28, 2025, and was awarded without a set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, has been awarded a delivery order by the Defense Logistics Agency (DLA) for Xolair 75 mg/0.5 mL auto-injector vials. The contract, valued at $1,277.01 with a firm fixed-price structure, is scheduled for completion by September 24, 2025. This delivery order was awarded without set-aside designation on September 3, 2025, and represents a continuation of DMS Pharmaceutical Group's...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $3,424.46 by the Defense Logistics Agency on September 11, 2025, for the supply of Xolair 300 mg/2 mL auto-injector units. The contract is structured as a firm fixed-price delivery order with an ultimate completion date of October 2, 2025, and no set-aside designation was applied to this procurement action. This delivery order is issued under...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $3,424.46 by the Defense Logistics Agency on April 24, 2025, for the supply of Xolair 300 mg/2 ml auto-injector units. The award utilizes a firm fixed-price contract type with no set-aside designation, with an ultimate completion date of May 15, 2025. This delivery order falls under DMS Pharmaceutical Group's larger Indefinite Delivery...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $8,561.15 by the Defense Logistics Agency (DLA) on September 15, 2025. The delivery order, which has an ultimate completion date of October 6, 2025, is for the supply of Xolair 300 mg/2 ml auto-injector syringes to support Department of Defense healthcare operations. This award carries no set-aside designation, allowing the...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $28.3K by the Defense Logistics Agency's Medical Supply Chain on August 27, 2025, for the supply of Xolair 300 mg/2 ml auto-injector units. This firm fixed-price delivery order is scheduled for completion by September 18, 2025, with no set-aside designation applied. The award represents a discrete fulfillment under DMS Pharmaceutical...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $10,273.38 by the Defense Logistics Agency on August 26, 2025, for the supply of Xolair 300 mg/2 ml auto-injector units. The contract carries no set-aside designation and is scheduled for completion by September 17, 2025, with performance taking place at the contractor's Park Ridge facility. This delivery order is issued...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order on August 26, 2025, by the Defense Logistics Agency for Xolair 300 mg/2 ml auto-injector medications. The contract is valued at $1,712.23 with a firm fixed-price structure and no set-aside designation. The delivery order is set to be completed by September 17, 2025, and represents a single purchase under DMS Pharmaceutical Group's larger Indefinite...
- SPE2DB22D9309Indefinite Delivery Contract
- SPE2DB22D9309-SPE2DB25FAF12Delivery Order
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $1,277.01 by the Defense Logistics Agency (DLA) on June 18, 2025, with an ultimate completion date of July 11, 2025. The contract covers the supply of Xolair 75 mg/0.5 ml auto-injector units and is structured as a firm fixed-price delivery order with no set-aside designation. This award is issued under DMS Pharmaceutical Group's larger single-award Indefinite Delivery Contract with the DLA under the SPE2DB program, valued at $499,999,999 and valid through November 2026, which enables the agency to procure a comprehensive range of pharmaceutical products for Department of Defense healthcare facilities worldwide. As a key supplier in the federal pharmaceutical supply chain, DMS Pharmaceutical Group has established a robust portfolio of contract awards with the DLA covering diverse medical products including prescription medications, biologics, auto-injectors, and specialty pharmaceuticals. The company's capability to supply Xolair, a biologic medication used for treating severe asthma and other allergic conditions, reflects its role in providing critical pharmaceutical products to support military health facility operations. The firm fixed-price structure ensures cost certainty for the government while leveraging the company's established relationship and performance under the larger IDC framework.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.3k | 6/18/25 |